Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:

NCT ID: NCT03667391 Recruiting - Clinical trials for The Geodemographics of CTEPH in Taiwan

Taiwan Cohort - Chronic ThromboEmbolic Pulmonary Hypertension Registry

Start date: January 17, 2018
Phase:
Study type: Observational [Patient Registry]

The diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) is difficult for numerous reasons and is related with a poor prognosis. In Taiwan, the incidence of CTEPH and its clinical features are unknown. This study aims at evaluating the prevalence, clinical characteristics, and management of CTEPH in a Taiwanese cohort. Primary objective: - To investigate the geodemographics of CTEPH in Taiwan Secondary objectives: - To characterize the demographics and clinical presentation of patients with CTEPH - To describe the real-world management and treatment outcome of patients with CTEPH - To identify the risk factors of CTEPH - To assess the relationship between risk factors/patients' characteristics and clinical outcomes for CTEPH - To evaluate the prognosis of CTEPH in Taiwan using survival assessment

NCT ID: NCT03666351 Recruiting - Hypertension Clinical Trials

Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease

Start date: August 21, 2018
Phase: Phase 4
Study type: Interventional

To compare changes in Left Ventricular Mass (LVM) depending on each blood pressure regulation between the intensive care group and the usual care group for patients with hypertension accompanied by aortic valve disease and evaluate an influence of blood pressure regulation on improvement of left ventricular hypertrophy and its safety

NCT ID: NCT03660397 Recruiting - Clinical trials for Uncontrolled Hypertension

Adrenal Artery Ablation for Uncontrolled Hypertension

Start date: August 1, 2018
Phase: Phase 3
Study type: Interventional

The activation of the renin-angiotensin-aldosterone system (RAAS) plays a key role in uncontrolled hypertension or resistant hypertension. Surgery and and medicine are the main treatment for primary aldosteronism(PA) by the current guidelines. However, only a small part of patients with PA meet the surgical criteria, and most of patients with uncontrolled hypertension and activation of RAAS have to take spironolactone or other antihypertensive drugs for long time. On the other side, long-term inhibition of aldosterone receptor may cause hyperkalemia, male breast hyperplasia and other adverse reactions. Moreover, hyperaldosterone is still not corrected by spironolactone, which causes extensive cerebrovascular damages even though blood pressure and blood potassium had been normalized. With the development of adrenal vein sampling and adrenal ablation, selective arterial ablation of adrenal gland(AAA) was observed with significant decrease of blood aldosterone and blood pressure in patients with PA, which made it promising that uncontrolled hypertension could be relieved by selective AAA.

NCT ID: NCT03659149 Recruiting - Hypertension Clinical Trials

Pharmacokinetics and Safety Profile of CKD-333

Start date: August 8, 2018
Phase: Phase 1
Study type: Interventional

Compare the pharmacokinetic characteristics and safety between CKD-333 tablet and CKD-330, D086 combination

NCT ID: NCT03657797 Recruiting - Clinical trials for Glaucoma, Open-Angle

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Start date: August 1, 2018
Phase: Phase 2
Study type: Interventional

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) will be compared to latanoprost 0.005% ophthalmic solution.

NCT ID: NCT03657550 Recruiting - Hypertension Clinical Trials

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

Start date: May 31, 2018
Phase: Phase 1
Study type: Interventional

This study are (1) to assess the relative bioavailability (BA) of a single oral dose of either 5 mg of Levamlodipine Maleate Tablets from CSPC or 10 mg of Amlodipine Besylate Tablet (NORVASC®) from Pfizer Inc. under fasting condition in male and female healthy subjects; and (2) to evaluate food effect on the PK profile of Levamlodipine Maleate Tablets from CSPC.

NCT ID: NCT03655288 Recruiting - Hypertension Clinical Trials

A Post-marketing Surveillance to Assess Safety and Efficacy of Twotopsplus.

Start date: July 25, 2017
Phase:
Study type: Observational [Patient Registry]

Post-marketing surveillance of Twotopsplus.

NCT ID: NCT03654378 Recruiting - Hypertension Clinical Trials

Nifedipine Metabolism in Pregnancy

Start date: August 1, 2018
Phase:
Study type: Observational

The objectives of this application are to provide mechanistic understanding of altered drug metabolism by hepatic cytochrome CYP3A4 and to translate the findings to human pregnancy. A drug metabolized by CYP3A4, Nifedipine, will be the drug of choice mechanism to understand the enzyme's induction. Pregnant women currently on Nifedipine to treat high blood pressure will be recruited. If the women enroll, the women will participate in four pharmacokinetic (PK) studies (one per trimester, and one postpartum).

NCT ID: NCT03653845 Recruiting - Hypertension Clinical Trials

Adrenal Artery Ablation for Primary Aldosteronism

Start date: July 1, 2018
Phase: Phase 3
Study type: Interventional

Primary aldosteronism (PA) is one of the most common causes of endocrine and resistant hypertension. Current studies have shown that the activation of the renin-angiotensin-aldosterone system (RAAS) and the increased sympathetic nerve activity in the central or local tissue are the key mechanisms of high blood pressure and its organ damages. The classical method for diagnosis of primary aldosteronism depends on the detection of peripheral venous blood aldosterone level, which is incapable of accurate positioning diagnosis. On the other hand, the current guidelines recommend that surgery and aldosterone receptor inhibitors were the only treatment for primary aldosteronism. However, only about 35% of aldosterone tumors and a small part of unilateral adrenal hyperplasia can be treated by surgery. More than 60% of idiopathic aldosteronism and bilateral adrenal hyperplasia need long-term drug therapy. However, long-term aldosterone inhibitor treatment may also cause hyperkalemia, male breast hyperplasia, female hirsutism and other adverse reactions. Therefore, the investigators proposed that endovascular chemical partial ablation of the adrenal gland can lower the aldosterone level, reduce the blood pressure and recover the potassium metabolism balance. In order to confirm the above effects, the investigators conduct an open, prospective, positive controlled study in patients with primary aldosteronism patients (including aldosterone, idiopathic aldosteronism and adrenal hyperplasia). The effects on blood pressure, blood electrolytes, adrenal hormones, metabolic indexes, target organ damages were observed to explore the efficacy and safety of the endovascular ablation of the adrenal gland in the treatment of primary aldosteronism.

NCT ID: NCT03651492 Recruiting - Renal Transplant Clinical Trials

Effects of Nocturnal Hypertension on Sleep Quality in Renal Transplant Recipients

Start date: June 1, 2017
Phase:
Study type: Observational

Nocturnal hypertension (i.e. blood pressure values >120/70 or 10% higher than diurnal values, as measured by ambulatory blood pressure monitoring, ABPM) is particularly frequent in renal transplant recipients (RTR), despite the use of antihypertensive drugs. Since RTR are also affected by several sleep disorders (like insomnia, restless legs syndrome, sleep apnoea) that frankly impair their quality of sleep (SQ), the aim of the present study is to ascertain whether a relationship exists between nocturnal hypertension and SQ. In fact, both nocturnal hypertension and sleep disorders may favour the onset or the progression of cardiovascular diseases, the first cause of death in RTR.